Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Sevilla – page 26

1 637 clinical trials in Sevilla, Spain across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Sevilla at a glance
1 637
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

1 637 trials in Sevilla

Open in trial search

Breast cancer+1

Recruiting

Study of inavolisib, letrozole and ribociclib in untreated early-stage breast cancer patients with PIK3CA mutation

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Inavolisib
  • Sponsor:F. Hoffmann-La Roche AG

Non-small cell lung cancer

Recruiting

Study comparing RMC-6236 and docetaxel in previously treated patients with advanced or metastatic non-small cell lung cancer who have RAS mutations

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Revolution Medicines Inc.

Autoimmune haemolytic anaemia

Recruiting

Study of rilzabrutinib tablets compared to placebo in adults with warm autoimmune hemolytic anemia

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Rilzabrutinib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

COVID-19

Recruiting

Study of ibuzatrelvir alone or combined with remdesivir in adults with COVID-19 who have severely compromised immune systems

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:IBUZATRELVIR
  • Sponsor:Pfizer Inc.

K-ras gene mutation+1

Recruiting

Study of MK-1084, cetuximab and mFOLFOX6 combination compared to mFOLFOX6 with or without bevacizumab for patients with KRAS G12C-mutant advanced colorectal cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Fallopian tube cancer+1

Recruiting

Study of mirvetuximab soravtansine dosing schedules for patients with platinum-resistant advanced ovarian, peritoneal, or fallopian tube cancer with high folate receptor expression

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Prednisolone Acetate
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

B-cell small lymphocytic lymphoma refractory+1

Recruiting

Study of sonrotoclax plus obinutuzumab or rituximab compared to venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:BeOne Medicines AG

Ovarian cancer

Recruiting

Study of trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance treatment for patients with HER2-expressing ovarian cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Daiichi Sankyo Inc.

Neovascular age-related macular degeneration+1

Recruiting

Study of Port Delivery System with ranibizumab given every 36 weeks in patients with neovascular age-related macular degeneration

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab
  • Sponsor:F. Hoffmann-La Roche AG

Transitional cell carcinoma

Recruiting

Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Triple negative breast cancer

Recruiting

Evaluating sacituzumab tirumotecan alone or with pembrolizumab compared to standard treatment in untreated patients with metastatic triple-negative breast cancer with low PD-L1 expression

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer

Recruiting

Study of visugromab and nivolumab with or without docetaxel as second-line treatment for patients with metastatic non-squamous non-small cell lung cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:CatalYm GmbH

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Sevilla

What the registry says about research in the country

01 Metabolic and Endocrine Disorders

Innovative research focusing on Type 1 Diabetes management and weight-related conditions, evaluating new therapeutic approaches for glycemic control and metabolic health.

  • Diabetes Management
  • Obesity Treatment
  • Metabolic Disorders

Studies aim to improve treatment outcomes for patients with complex metabolic conditions.

02 Neurological Conditions

Advanced clinical trials examining treatments for Multiple Sclerosis and neurodegenerative disorders, including pioneering research in Frontotemporal Dementia and Parkinson's disease.

  • Multiple Sclerosis Therapies
  • Neurodegenerative Diseases
  • Brain Health Innovation

Research focuses on developing targeted treatments for various neurological conditions.

03 Infectious Diseases

Comprehensive vaccine development programs targeting Influenza, Cytomegalovirus, and meningococcal infections, with emphasis on preventive medicine.

  • Vaccine Development
  • Viral Infections
  • Immunization Studies

Studies aim to enhance vaccine efficacy and immune response across different age groups.

04 Oncology Research

Groundbreaking studies in cancer treatment, including research on bladder cancer and mantle cell lymphoma, exploring combination therapies and targeted treatments.

  • Cancer Immunotherapy
  • Targeted Therapies
  • Combination Treatments

Focus on developing innovative approaches to improve cancer treatment outcomes.

05 Autoimmune Conditions

Clinical investigations into Psoriatic Arthritis and inflammatory conditions, evaluating novel therapeutic approaches and treatment combinations.

  • Arthritis Treatment
  • Inflammatory Diseases
  • Immune System Disorders

Research aims to develop more effective treatments for chronic autoimmune conditions.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.